Policy & Regulation
Adimab partner GSK receives additional marketing approvals for depemokimab
16 April 2026 - Adimab LLC, a provider of therapeutic antibody discovery and engineering technologies, said on Wednesday that it congratulates biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) fo...
Seragon reports SRN-901 longevity drug data
16 April 2026 - Research-based biopharmaceutical company Seragon Biosciences Inc announced on Wednesday the publication of comprehensive preclinical study results in the peer-reviewed journal Drug Des...
Lunai Bioworks and Geneial enter into LOI to build rare disease patient cohorts for drug development partnerships
15 April 2026 - AI-driven drug discovery company Lunai Bioworks Inc (NASDAQ: LNAI) reported on Wednesday that it has entered into a non-binding Letter of Intent through its BioSymetrics subsidiary wit...
Circio partners with Acuitas to evaluate in vivo CAR-T cell therapy technology
15 April 2026 - Biotechnology company Circio Holding ASA (OSE:CRNA) announced on Wednesday that it has entered into an evaluation agreement with Canadian biotechnology company Acuitas Therapeutics to ...
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
15 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) reported on Wednesday that it has completed the acquisition of 35Pharma Inc, a Canada-based clinical-stage biopharmaceutical co...
Poolbeg Pharma secures MHRA approval for POLB 001 trial as US research highlights multi-billion dollar potential
15 April 2026 - Biopharmaceutical company Poolbeg Pharma plc (AIM: POLB) announced on Wednesday that it has received Clinical Trial Authorisation from the UK Medicines and Healthcare products Regulato...